Health ❯ Healthcare ❯ Clinical Trials ❯ Phase 3 Trials

Eli Lilly

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

Unusually large, sustained reductions reported by Lilly could reshape obesity treatment if regulators approve the drug this year.

FDA Clears 7.2‑mg Wegovy as India Enters Generic Semaglutide Era